IL6 and ovarian carcinoma: Indeed, knockdown of LPA2 or LPA3 decreases IL-6 production, and their over-expression leads to increased serum levels of IL-6 and VEGF, increased tumor burden and shortened survival times in a mouse model of ovarian cancer peritoneal metastasis; modulation of LPA1 had no significant effect in this study [11].